Transaction in Own Shares

Dr. Martens PLC
17 July 2023
 

                                                                                                          

DR. MARTENS PLC


TRANSACTIONS IN OWN SECURITIES

 

 

 

Dr. Martens plc ("Dr. Martens") announces today that it has purchased the following number of its ordinary shares of 1 pence each on the London Stock Exchange and Multilateral Trading Facilities from Morgan Stanley & Co. International plc ("Morgan Stanley"). Such purchase forms part of the Company's existing share buyback programme and was effected pursuant to the instructions issued by the Company on 1 June 2023, as announced on 14 July 2023:

 

 

Ordinary Shares

 

Date of purchase:

17 July 2023

Number of ordinary shares purchased:

74,780

Highest price paid per share:

132.30p

Lowest price paid per share:             

129.40p

Volume weighted average price paid per share:

131.20p

 

 

Dr. Martens intends to cancel the purchased shares.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a full breakdown of the individual trades made by Morgan Stanley on behalf of the Company as part of the share buyback programme is set out in the Schedule to this announcement available through the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/2855G_1-2023-7-17.pdf

 

 

For further information please contact:

 

Paul Rolling

Assistant Company Secretary

+447584 243562

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Dr. Martens (DOCS)
UK 100

Latest directors dealings